By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Kadmon Corporation (Formerly Known As Kadmon Pharmaceuticals) 

Alexandria Center for Life Sciences
450 East 29th Street, 5th Floor
New York  New York  10016  U.S.A.
Phone: 212-308-6000 Fax: n/a




Company News
Convicted ImClone Systems (LLY) Boss Becomes Chief Of Innovation At Kadmon Corporation While Brother Harlan W. Waksal, M.D Takes CEO Post 9/24/2014 8:16:08 PM
Kadmon Corporation Initiates Phase 2a Portion Of KD020 Study In Autosomal Dominant Polycystic Kidney Disease 6/19/2014 11:41:08 AM
Kadmon Corporation Announces National Institutes of Health (NIH) Agreement To Evaluate Gene Therapy Program 6/16/2014 11:08:38 AM
Kadmon Corporation Announces The Initiation Of A Phase 1b/2a Study Of KD019 And Trastuzumab In HER2-Positive Metastatic Breast Cancer 6/4/2014 9:03:53 AM
Kadmon Corporation To Present At Jefferies and Co. 2014 Global Healthcare Conference 5/30/2014 9:35:00 AM
Kadmon Corporation Presents Results Of KD025 Preclinical And Clinical Studies At AAI Annual Meeting 5/5/2014 10:06:19 AM
Kadmon Corporation Announces The Initiation Of KD025 Phase 2 Program In Psoriasis 4/8/2014 10:32:36 AM
Kadmon Corporation Presents Preclinical Results Demonstrating KD019 Activity In Trastuzumab Resistant HER2+ Breast Cancer 4/8/2014 10:26:44 AM
Kadmon Corporation Presents Results At The 9th International Congress On Autoimmunity Demonstrating The Effects Of KD025 On Immune Homeostasis 3/28/2014 8:23:27 AM
Kadmon Pharmaceuticals Announces Co-Promotion Agreement With Valeant Pharmaceuticals North America And For SYPRINE® (Trientine Hydrochloride) In Wilson's Disease 2/25/2014 10:28:07 AM